109 related articles for article (PubMed ID: 37699162)
1. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
Keam B; Hong MH; Shin SH; Heo SG; Kim JE; Ahn HK; Lee YG; Park KU; Yun T; Lee KW; Kim SB; Lee SC; Kim MK; Cho SH; Oh SY; Park SG; Hwang S; Nam BH; Kim S; Kim HR; Yun HJ;
J Clin Oncol; 2024 Feb; 42(5):507-517. PubMed ID: 37699162
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Kim KH; Lim SM; Ahn HK; Lee YG; Lee KW; Ahn MJ; Keam B; Kim HR; Lee HW; An HJ; Kim JS
Cancer Res Treat; 2024 Jan; 56(1):37-47. PubMed ID: 37475136
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S; Li W; Wu S; Stewart R; Morsli N; Raja R; Zhang Q; Ye J; He P; Shetty J; Yovine A; Holoweckyj N; Real K; Walker J; Wrona M; de Los Reyes M; Barker C; Whiteley J; Haddad R; Licitra L; Ferris R; Fayette J; Zandberg DP; Siu LL; Mesía R
Clin Cancer Res; 2023 Jun; 29(11):2066-2074. PubMed ID: 36806911
[TBL] [Abstract][Full Text] [Related]
9. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
Bauman JE; Saba NF; Roe D; Bauman JR; Kaczmar J; Bhatia A; Muzaffar J; Julian R; Wang S; Bearelly S; Baker A; Steuer C; Giri A; Burtness B; Centuori S; Caulin C; Klein R; Saboda K; Obara S; Chung CH
J Clin Oncol; 2023 Aug; 41(22):3851-3862. PubMed ID: 36977289
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract][Full Text] [Related]
13. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial.
Gulati S; Crist M; Riaz MK; Takiar V; Lehn M; Monroe I; Palackdharry S; Kurtzweil N; Jandarov R; Harun N; Wise-Draper TM
Clin Cancer Res; 2023 May; 29(10):1906-1915. PubMed ID: 36802410
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
Lee JY; Kim BG; Kim JW; Lee JB; Park E; Joung JG; Kim S; Choi CH; Kim HS;
J Gynecol Oncol; 2022 Jul; 33(4):e45. PubMed ID: 35320892
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z
Front Immunol; 2023; 14():1302840. PubMed ID: 38299153
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Kim H; Park S; Jung HA; Lee SH; Park K; Ahn YC; Oh D; Ahn MJ
Cancer Res Treat; 2023 Oct; 55(4):1104-1112. PubMed ID: 37202212
[TBL] [Abstract][Full Text] [Related]
19. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
[TBL] [Abstract][Full Text] [Related]
20. A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma.
Swiecicki PL; Durm G; Bellile E; Bhangale A; Brenner JC; Worden FP
Invest New Drugs; 2020 Oct; 38(5):1550-1558. PubMed ID: 31981071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]